Johnson & Johnson (JNJ) — Fair Value Analysis
Base-case fair value (P50): $207.45 · Current price: $226.71 · Verdict: Fairly Valued
The Verdict on JNJ
Our Monte Carlo simulations indicate that Johnson & Johnson (JNJ) is currently overvalued. With a current price of $223.97, the Healthcare giant trades significantly above its median fair value (P50) of $183.85. This represents a substantial -17.9% divergence from what our models suggest is its intrinsic worth, underscoring a notable disconnect between market price and calculated fair value. Investors considering JNJ at its current valuation should note this premium.
How JNJ stacks up against Healthcare
Despite its dominant position within the Healthcare sector, JNJ's operational and financial health is categorized as "average" when compared to its industry peers. This quality tier assessment suggests that while JNJ is a robust company, it doesn't possess a distinct qualitative edge that would inherently justify its current trading premium. The median fair value of $183.85, derived from thousands of simulated forward scenarios, reflects this operational reality and contrasts sharply with the $223.97 current market price.
What this means for investors
The Monte Carlo simulation-derived fair value for JNJ, showing a -17.9% overvaluation at its $223.97 current price compared to a $183.85 P50, presents a challenging entry point for new capital. For existing shareholders, this premium suggests limited upside in a bull case and potential vulnerability in a downside scenario. Given its "average" quality tier relative to the Healthcare sector, investors should exercise caution. To see the full bear and bull distribution and track JNJ's fair value as new fundamentals are released, sign up for a free FairCurve account today.
Frequently Asked Questions
Is JNJ overvalued or undervalued right now?
Based on our Monte Carlo simulations, Johnson & Johnson (JNJ) is currently overvalued, with a median fair value (P50) of $183.85 compared to its current price of $223.97.
What is the bear case and bull case for JNJ?
The full Monte Carlo distribution, including specific bear-case (P10) and bull-case (P90) price targets, as well as the probability of upside, is available with a free FairCurve account. We do not publish these specific dollar values externally.
How does FairCurve calculate JNJ's fair value?
FairCurve calculates JNJ's fair value using advanced Monte Carlo simulations that project thousands of potential forward scenarios, evaluating the company's intrinsic value under various market conditions.
How can I track JNJ's fair value as it changes?
You can add JNJ to a free FairCurve watchlist to receive daily fair-value updates and instant re-valuation when new earnings or significant fundamental data are released.